Anti-Spike Monoclonal Antibody Therapy in Pregnant Women With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Thilagar, Bright; Ghosh, Aditya; Nguyen, Jerome; Theiler, Regan N.; Wick, Myra J.; Hurt, Ryan T.; Razonable, Raymund R.; Ganesh, Ravindra

doi:10.1097/aog.0000000000004700

Cited by 26 publications

(23 citation statements)

References 13 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently some reports on pregnant women treated with mAbs have become available, the majority of whom do not report concerning adverse effect and good efficacy [23][24][25][26][27]. This is not a surprise, as immunoglobulins in pregnancy have been largely used to prevent haemolyses caused by maternal/foetal RhD-incompatibility [28].…”

Section: Discussionmentioning

confidence: 99%

Treatment with anti-SARS-CoV-2 monoclonal antibodies in pregnant and postpartum women: first experiences in Florence, Italy

et al. 2022

View full text Add to dashboard Cite

Purpose Pregnant and postpartum women are at increased risk of developing severe COVID-19. Monoclonal antibodies (mAbs) are now widely used in high-income countries to treat mild to moderate COVID-19 outpatients at risk for developing severe disease. Very few data are available on the use of mAbs in special populations, including pregnant and postpartum women. Here we present our early experience with mAbs in these two populations. Methods Electronic records of pregnant and postpartum women treated with mAbs at Careggi University Hospital, Florence, were retrieved. Relevant data were extracted (age, presence of risk factors for COVID-19, oxygen support, mAb type, gestational age, and pregnancy status). When available, outcomes at 28 days after administration were also included. Results From March 1st to September 30th 2021, eight pregnant and two postpartum women have been treated with mAbs at our center. The median age was 31 years (IQR 30–33.5, range 29–38), median gestational age was 24 weeks. Seven patients had additional risk factors. According to the Italian disposition, all patients received casirivimab/imdevimab, with five receiving a 2.4 mg dose and five receiving a 8 g dose. Eight patients improved. One developed myocarditis, considered a COVID-19 complication. Another required a transient increase of low flow oxygen support before improving and being discharged. At a 28 days follow-up, all patients were clinically recovered. We did not observe mAbs related adverse events. Conclusion Although preliminary data should be interpreted with caution, it is remarkable how mAbs were well tolerated by pregnant women with COVID-19. Further data on mAbs in this special population should be collected but the use of mAbs in pregnant and postpartum patients should be considered. Even thus oral antivirals are becoming available, they are not recommended in pregnant and postpartum women. This population may specifically benefit from treatment with last generation mAbs.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment with anti-SARS-CoV-2 monoclonal antibodies in pregnant and postpartum women: first experiences in Florence, Italy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Managing COVID-19 in pregnant patients has imposed a big challenge, especially due to absence of largescale clinical trials. Previously, only a few retrospective case reports and case series have been published with experience in using banlanivimab/etesevimab and casirivimab/imdevimab in pregnant women [16][17][18][19][20].…”

Section: Discussionmentioning

confidence: 99%

Use of Sotrovimab in a Pregnant Patient With COVID-19 Infection

Gupta¹,

Perez²

2022

Cureus

View full text Add to dashboard Cite

For individuals with mild-to-moderate coronavirus disease 2019 (COVID-19, caused by severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]), monoclonal antibodies (MOABs) are known to prevent progression of the disease and hospitalization. Pregnant women, who are at an increased risk of severe COVID-19 infection, have been significantly underrepresented in studies for MOAB treatments, especially sotrovimab. Specifically, there has only been one case reported of a pregnant woman using sotrovimab successfully. We report a second such patient -an unvaccinated 21-year-old, COVID-19-positive, 16-week pregnant woman who was followed closely over the next 60 days post-MOAB infusion. We noted prevention in the progression of the disease and hospitalization without any fetal/pregnancy-related complications.

show abstract

“…There were no adverse drug reactions and both women recovered without developing severe COVID-19. Additionally, a case series of 51 pregnant women who received either bamlaniviab (14%), bamlanivimab-etesevimab (7%) or casirvimab-imdevimab (79%) anti-spike mAb therapy for mild-to-moderate COVID-19 at a mean gestational age at infusion of 25.7±10.1 weeks (Thilagar et al, 2022). There were no immediate adverse effects and no patient had COVID-19 progression.…”

Section: • Sars-cov-2mentioning

confidence: 99%

Maternal immune protection against infectious diseases

Langel

Blasi²,

Permar³

2022

Cell Host & Microbe

View full text Add to dashboard Cite

Anti-Spike Monoclonal Antibody Therapy in Pregnant Women With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Abstract: BMI, body mass index. Data are median [interquartile range], n (%), or mean6SD.

Cited by 26 publications

References 13 publications

Treatment with anti-SARS-CoV-2 monoclonal antibodies in pregnant and postpartum women: first experiences in Florence, Italy

Treatment with anti-SARS-CoV-2 monoclonal antibodies in pregnant and postpartum women: first experiences in Florence, Italy

Use of Sotrovimab in a Pregnant Patient With COVID-19 Infection

Maternal immune protection against infectious diseases

Contact Info

Product

Resources

About